CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Dec. 14, 2022—Qiagen announced FDA approval of its Therascreen KRAS RGQ PCR kit as a companion diagnostic test to aid in identifying non-small cell lung cancer patients who are eligible for treatment with adagrasib (Krazati, Mirati Therapeutics).
Pages: 1 2